Adaptimmune is a leader in TCR T-cell therapy, focused on designing and delivering novel cancer immunotherapy products. We utilize the body’s own machinery – the T-cell – to target and destroy cancer cells. We believe our therapies have the potential to significantly impact cancer treatment and clinical outcomes of people with cancer.
We have developed a proprietary T-cell receptor (TCR) platform that enables us to identify cancer targets, as well as find and genetically engineer TCRs to recognize and attack these targets. We engineer a patient’s own T-cells to express these affinity-enhanced TCRs, to produce TCR T-cell treatments that we call SPEAR (Specific Peptide Enhanced Affinity Receptor) T-cell therapies. We began rolling submission of a BLA for afami-cel for the treatment of people with synovial sarcoma in late 2022 and aim to complete the submission in Q4 2023.
Our translational science team evaluates our manufactured products, as well as tumor and blood samples from patients collected before and after SPEAR T-cell treatment. This enables us to monitor how our SPEAR T-cells perform and persist in patients, and to examine how the properties of the cells relate to clinical responses. Learnings from our translational research have led to the development of multiple next-generation approaches. Our first next-generation cell therapy targeting MAGE-A4, ADP-A2M4CD8, is currently being evaluated in the SURPASS and SURPASS-2 trials.
We have a deep preclinical pipeline with multiple autologous and allogeneic cell therapy approaches, including new next-generation SPEAR T-cells, more TCR targets, broader HLA coverage, HLA Independent TCRs or HiT therapies eliminating the need for HLA restriction; and next-generation Tumor Infiltrating Lymphocytes (TILs) therapies.
The challenges and opportunities of cell therapy demand specific internal capabilities. Adaptimmune has been built as an integrated cell therapy company, from the ground up, with the sole purpose of designing and delivering cell therapies for people with cancer.
SPEARHEAD-1 pivotal trial with afami-cel for people with synovial sarcoma met primary endpoint
Overall response rate of 36% with next-gen MAGE-A4 targeted SPEAR T-cells in the SURPASS trial reported at ESMO 2021 – responses in ovarian, head and neck, esophagogastric junction, bladder cancers, and synovial sarcoma
Initiated a Phase 2 trial, SURPASS-2, for people with esophageal or esophagogastric junction (EGJ) cancers.
First preclinical data from mesothelin HiT (HLA-independent TCRs) program demonstrated antigen-specific tumor cell killing in vitro and complete tumor regression in an animal model
Initiated a strategic collaboration for allogeneic T-cell therapies with Genentech and $150 million upfront payment received
Allogeneic platform progress with confirmed differentiation of human induced pluripotent stem cells (hiPSCs) into functional α/β iT-cells that can repeatedly kill MAGE-A4 expressing target cells in vitro.
Responses in six solid tumor indications
Complete response in first patient treated with ADP-A2AFP in Cohort 3
Partnership with Astellas to develop allogeneic cell therapies
~$90M raised via secondary public offering in January
~$240M raised via public offering in June
Responses with ADP-A2M4 in synovial sarcoma and antitumor activity in other solid tumors with ADP-A2M4, ADP-A2M10, ADP-A2AFP
SPEARHEAD-1 trial started 2H19 (synovial sarcoma and myxoid/round cell liposarcoma [MRCLS])
SURPASS (first next-gen candidate) started 2H19
Collaboration with Alpine Immune Sciences
Agreement with Noile-Immune Biotech
Registered Direct Offering (RDO) of ~$100M
Transition of NY-ESO SPEAR T-cell Therapy Program to GSK complete
Opening of UK Vector Manufacturing Facility at Catapult in Stevenage
Option exercise by GSK for exclusive license to NY-ESO SPEAR T-cell program
Completion of public offering with net proceeds of $61,397,000
Breakthrough therapy designation and PRIME regulatory access for NY-ESO SPEAR T-cell therapy
*NY-ESO program was transitioned to GSK in August 2018
TCR technology developed at Oxford University
Avidex was formed on the basis of T-cell receptor technology from Oxford University
Avidex was acquired by Medigene
Adaptimmune spun out as a virtual company with University of Penn collaboration
Adaptimmune establishes R&D infrastructure and delivers promising clinical data
Strategic collaboration with GSK + $104M Series A Funding Round